Advanced Search

Home > Journals > European Journal of Physical and Rehabilitation Medicine > Past Issues > Articles online first > European Journal of Physical and Rehabilitation Medicine 2016 Nov 11

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEEUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE

A Journal on Physical Medicine and Rehabilitation after Pathological Events


Official Journal of the Italian Society of Physical and Rehabilitation Medicine (SIMFER), European Society of Physical and Rehabilitation Medicine (ESPRM), European Union of Medical Specialists - Physical and Rehabilitation Medicine Section (UEMS-PRM), Mediterranean Forum of Physical and Rehabilitation Medicine (MFPRM), Hellenic Society of Physical and Rehabilitation Medicine (EEFIAP)
In association with International Society of Physical and Rehabilitation Medicine (ISPRM)
Indexed/Abstracted in: CINAHL, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,063

 

European Journal of Physical and Rehabilitation Medicine 2016 Nov 11

Efficacy and safety of Botulinum Toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis

Yan DONG 1, 2, Tao WU 3, Xiaohua HU 2, Tong WANG 4

1 Nanjing Medical University, Nanjing, PR China; 2 Department of Rehabilitation Medicine, Hangzhou Hospital of Zhejiang Chinese Armed Police Force, Hangzhou, PR China; 3 Department of Rehabilitation Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 4 Department of Rehabilitation Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China

INTRODUCTION: Muscle spasticity is a positive symptom after stroke and traumatic brain injury. Botulinum Toxin type A injection is widely used for treating post stroke and traumatic brain injury spasticity. This study aimed to evaluate efficacy and safety of Botulinum Toxin type A for upper limb spasticity after stroke and traumatic brain injury and investigate reliability and conclusiveness of available evidence for Botulinum Toxin type A intervention.
EVIDENCE ACQUISITION: We searched electronic databases from inception to September 10 of 2016. Randomized controlled trials comparing the effectiveness between Botulinum Toxin type A and placebo in stroke or traumatic brain injury adults with upper limb spasticity were included. Reliability and conclusiveness of the available evidence were examined with trial sequential analysis.
EVIDENCE SYNTHESIS: From 489 citations identified, 22 studies were included, reporting results for 1804 participants. A statistically significant decrease of muscle tone was observed at each time point after Botulinum Toxin type A injection compared to placebo (SMD at week4 = -0.98, 95% CI: -1.28 to -0.68; I2=66%, p=0.004; SMD at week 6 = -0.85, 95% CI: -1.11 to -0.59, I2=1.2%, p=0.409; SMD at week 8 = -0.87, 95% CI: -1.15 to -0.6, I2=0%, p=0.713; SMD at week 12 = -0.67, 95% CI: -0.88 to -0.46, I2=0%, p=0.896; and SMD over week 12 = -0.73, 95% CI: -1.21 to -0.24,I2=63.5%, p=0.065).Trial sequential analysis showed that as of year 2004 sufficient evidence had been accrued to show significant benefit of Botulinum Toxin type A four weeks after injection over placebo control. Botulinum Toxin type A treatment also significantly reduced Disability Assessment Scale score than placebo at 4, 6 and 12-week follow-up period (WMD = -0.33, 95%CI: -0.63 to -0.03, I2=60%, p=0.114; WMD =-0.54, 95%CI: -0.74 to -0.33, I2= 0%, p=0.596 and WMD =-0.3, 95%CI: -0.45 to -0.14, I2= 0%, p=0.426 respectively), and significantly increased patients’ global assessment score at week 4 and 6 after injection (SMD = 0.56, 95% CI: 0.28 to 0.83; I2=0%, p=0.681 and SMD = 1.11, 95% CI: 0.4 to 1.77; I2=72.8%, p=0.025 respectively). No statistical difference was observed in the frequency of adverse events between Botulinum Toxin type A and placebo group (RR =1.36, 95% CI [0.82, 2.27]; I2=0%, p=0.619).
CONCLUSIONS: As compared with placebo, Botulinum Toxin type A injections have beneficial effects with improved muscle tone and well-tolerated treatment for patients with upper limb spasticity post stroke or traumatic brain injury.

language: English


FULL TEXT  REPRINTS

top of page